In this regard, a positive correlation between cetuximab (Cmab) skin rash and tumor response rate and survival has been reported [28], and it is considered that the incidence and severity of skin rash is closely related to the efficacy of anti-EGFR antibody. This evidence concerns the gene EGFR and neoplasm.